Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06615479 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
A Phase 3 study of Relapsed or Refractory Multiple Myeloma (RRMM), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT06615479 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma (RRMM) that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 440 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT06615479, a Phase 3 study of Relapsed or Refractory Multiple Myeloma (RRMM), is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG BMS-986393
Study Locations (20)
Florida
- Baptist MD Anderson Cancer Center - Jacksonville
- Local Institution - 0130 - Miami
- Local Institution - 0228 - Orlando
California
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- Local Institution - 0050 - Orange
New York
- Local Institution - 0229 - New York
- Local Institution - 0221 - Stony Brook
North Carolina
- Local Institution - 0067 - Charlotte
- Local Institution - 0216 - Winston-Salem
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- Local Institution - 0232 - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
District of Columbia
- Local Institution - 0223 - Washington D.C.
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2032-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06615479
The ClinicalTrials.gov registry entry for NCT06615479 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma (RRMM) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06615479 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT06615479 about?
NCT06615479 is a clinical study titled "A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)". The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
What is the current status of trial NCT06615479?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2025-03-12. Estimated completion is 2032-06-22.
What conditions does trial NCT06615479 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma (RRMM).
What interventions are being tested in trial NCT06615479?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), BMS-986393 (DRUG).
Who is sponsoring clinical trial NCT06615479?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06615479 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.